Pailin Biopharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
000403SZSE
Progress Announcement on Share Repurchase by the Company
✨ AI Summary
The company announced its share repurchase plan, approved on April 27, 2026, with a budget of between RMB 200 million and RMB 300 million. As of May 31, 2026, the company repurchased 1,816,380 shares, representing 0.19% of total shares, at prices ranging from RMB 11.98 to RMB 12.40 per share. The repurchased shares will be used for employee stock ownership and incentive plans.
Summary generated by AI · Always verify with source document
Exchange Summary
SHARE REPURCHASEAs of 31 May 2026, the Company has repurchased 1816380 public shares, accounting for 0.19 percent of the Company's total capital stock. The highest repurchase price was CNY12.4 per share and the lowest was CNY11.98 per share.
Provided by Shenzhen Stock Exchange
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.